Radiopharm pipeline ‘dramatically’ undervalued, says JonesResearch

JonesResearch analyst Justin Walsh reiterates a Buy rating on Radiopharm (RADX) and announced a $30 price target on the U.S. shares. The firm remains “intrigued” by the potential of the company’s “diverse” radiopharmaceutical pipeline and believes the market is “dramatically undervaluing the opportunity.”